clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stolte M et al. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. 1998 Z Gastroenterol pmid:9773482
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Mukunda BN et al. Clarithromycin therapy for bacillary peliosis did not prevent bacillary angiomatosis. 1998 Clin. Infect. Dis. pmid:9770180
Laine L et al. Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. 1998 Aliment. Pharmacol. Ther. pmid:9768532
Louw JA et al. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9768531
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Mégraud F and Doermann HP Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. 1998 Gut pmid:9764043
Hawkey CJ et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. 1998 Lancet pmid:9759744
Pontani D et al. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. 1998 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9758284
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Greenblatt DJ et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998 Clin. Pharmacol. Ther. pmid:9757151
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Apseloff G et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. 1998 J Clin Pharmacol pmid:9753212
Huang WH et al. New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. 1998 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9745160
Hiratsuka T et al. [Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone]. 1998 Nihon Kokyuki Gakkai Zasshi pmid:9742869
Sevin E et al. Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR. 1998 FEMS Microbiol. Lett. pmid:9742711
Siu LK et al. Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori. 1998 J. Clin. Microbiol. pmid:9738066
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Lamouliatte H et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. 1998 Am. J. Gastroenterol. pmid:9732938
Chu KM et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. 1998 Am. J. Gastroenterol. pmid:9732921
Vakil N et al. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. 1998 Am. J. Gastroenterol. pmid:9732920
Lanza FL et al. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. 1998 Helicobacter pmid:9731994
Bazzoli F et al. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. 1998 Helicobacter pmid:9731991
Graham DY et al. Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. 1998 Helicobacter pmid:9731987
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Gorski JC et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. 1998 Clin. Pharmacol. Ther. pmid:9728893
Bermudez LE et al. Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. 1998 J. Infect. Dis. pmid:9728568
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Sung JJ et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9726384
Nelson KG et al. Results of operation in Mycobacterium avium-intracellulare lung disease. 1998 Ann. Thorac. Surg. pmid:9725364
Venuta A et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. 1998 Jun-Jul J. Int. Med. Res. pmid:9718470
Tanahashi T et al. Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. 1998 J. Gastroenterol. Hepatol. pmid:9715426
Cecchi R and Torelli E Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. 1998 J. Dermatol. pmid:9714985
Améndola R et al. [Is dental plaque a normal Helicobacter pylori reservoir?]. 1998 Acta Gastroenterol. Latinoam. pmid:9713656
Bergmann JS and Woods GL In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. 1998 Int. J. Tuberc. Lung Dis. pmid:9712275
Fernández Bermejo M and García Grávalos R [Ebrotidine in the eradicating treatment of H. pylori]. 1998 Jun-Jul Gastroenterol Hepatol pmid:9711019
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Wang G et al. Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. 1998 J. Clin. Microbiol. pmid:9705423
Ellenrieder V et al. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9701524
Takizawa H et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. 1998 Eur. Respir. J. pmid:9701415
Fennerty MB et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. 1998 Aug 10-24 Arch. Intern. Med. pmid:9701099
Hsieh PF et al. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori. 1998 J. Formos. Med. Assoc. pmid:9700240
Wakasugi H et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. 1998 Clin. Pharmacol. Ther. pmid:9695727
Hashimoto Y [Eradication therapies for Helicobacter pylori]. 1998 Kansenshogaku Zasshi pmid:9695480
Habu Y et al. Triple therapy with omeprazole, amoxicillin and clarithromycin is effective against Helicobacter pylori infection in gastric ulcer patients as well as in duodenal ulcer patients. Results of a randomized controlled trial in Japan. 1998 Jul-Aug Digestion pmid:9693202
Dobrilla G et al. Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692703
Catalano F et al. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692702
Bardhan KD et al. Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9692693
Soepandi P et al. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. 1998 Respirology pmid:9692520
Bigard MA et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9690730
Portaels F et al. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9687409
Martin SJ and Pendland SL Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. 1998 J. Antimicrob. Chemother. pmid:9687103
Bordet AL et al. [Mycobacterium chelonae cutaneous infection: efficacy of prolonged treatment by clarithromycin]. 1997 Ann Dermatol Venereol pmid:9686059
Tonai A et al. [Clarithromycin suppression of DNA synthesis by rat nasal mucosal cells enhanced by endotoxin instillation]. 1997 Jpn J Antibiot pmid:9678983
Grübel P and Cave DR Factors affecting solubility and penetration of clarithromycin through gastric mucus. 1998 Aliment. Pharmacol. Ther. pmid:9678818
Ahuja V et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. 1998 Aliment. Pharmacol. Ther. pmid:9678815
Louw JA et al. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. 1998 Aliment. Pharmacol. Ther. pmid:9678814
Cammarota G et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. 1998 Aliment. Pharmacol. Ther. pmid:9678813
Ricciardiello L et al. Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9678812
Talley NJ et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9678811
Perri F et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. 1998 Ital J Gastroenterol Hepatol pmid:9675647
Dunne EF et al. Streptomyces pneumonia in a patient with human immunodeficiency virus infection: case report and review of the literature on invasive streptomyces infections. 1998 Clin. Infect. Dis. pmid:9675460
Dore MP et al. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. 1998 Clin. Infect. Dis. pmid:9675458
de Boer WA et al. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. 1998 Am. J. Gastroenterol. pmid:9672338
Sanfélix Genovés J et al. [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. 1998 Aten Primaria pmid:9670578
Miyaji H et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. 1997 Aliment. Pharmacol. Ther. pmid:9663841
Kolkman JJ et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9663840
Goh KL et al. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? 1997 Aliment. Pharmacol. Ther. pmid:9663838
Pozzato P et al. Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9663724
Bazzoli F et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. 1998 Aliment. Pharmacol. Ther. pmid:9663723
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
Amsden GW et al. Oral cimetidine prolongs clarithromycin absorption. 1998 Antimicrob. Agents Chemother. pmid:9660986
Klein JO Clarithromycin and azithromycin. 1998 Pediatr. Infect. Dis. J. pmid:9655546
Wiedermann BL Macrolides: clarithromycin and azithromycin. 1998 Pediatr Rev pmid:9654947
Moshkowitz M et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. 1998 Pediatrics pmid:9651466
Parente F et al. Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. 1998 Scand. J. Gastroenterol. pmid:9648983
Nakamura T et al. [Topics on Helicobacter pylori (discussion)]. 1998 Nippon Naika Gakkai Zasshi pmid:9648442
Sato R et al. [Problems following antibiotic therapy for eradication of Helicobacter pylori]. 1998 Nippon Naika Gakkai Zasshi pmid:9648440
Aoyama N [Efficacy of antibiotic therapy in eradicating Helicobacter pylori]. 1998 Nippon Naika Gakkai Zasshi pmid:9648439
Kimura K and Sato K [Recent topics on Helicobacter pylori--Historic background and problems caused by bacteria]. 1998 Nippon Naika Gakkai Zasshi pmid:9648427
Shimoyama T et al. [Antibiotic therapy in eradicating Helicobacter pylori infections]. 1998 Nippon Naika Gakkai Zasshi pmid:9648426
Wharton JR et al. Erythrasma treated with single-dose clarithromycin. 1998 Arch Dermatol pmid:9645634
Makhani S et al. Atypical cervico-facial mycobacterial infections in childhood. 1998 Br J Oral Maxillofac Surg pmid:9643597
Grove DI et al. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. 1998 Pathology pmid:9643503
Gray VS Syncopal episodes associated with cisapride and concurrent drugs. 1998 Ann Pharmacother pmid:9640482
Nordt SP et al. Clarithromycin induced digoxin toxicity. 1998 J Accid Emerg Med pmid:9639187
Burman WJ et al. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. 1998 Diagn. Microbiol. Infect. Dis. pmid:9635911
Calvet Calvo X [Treatment of Helicobacter pylori infections]. 1998 Gastroenterol Hepatol pmid:9633184
Miwa H et al. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. 1998 Helicobacter pmid:9631313
Battaglia G et al. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. 1998 Helicobacter pmid:9631310
Fireman Z et al. Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel. 1998 Helicobacter pmid:9631306
Domingo D et al. High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. 1998 J. Antimicrob. Chemother. pmid:9630414